The Wall Street Journal: House Committee takes on AbbVie’s pricing, patents for top-selling drug Humira
AbbVie Inc.’s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs.
